Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study
Authors' conclusion
We evidenced, for the first time to the best of our knowledge, the favorable effects on cognitive impairment of extended-release metformin in frail women with diabetes and hypertension.
Study context
- Population
- Consecutive frail older women with hypertension and DM, ASL Avellino, Italy, June 2021–August 2022completed the study
- Participants
- 145 women
- Exposure
- Extended-release metformin vs no treatment in frail older women; controls: men on extended-release metformin, women on regular metformin
- Outcome
- Cognitive performance
- Follow-up
- 6-month follow-up
Methodological detailsconsecutive patients, preliminary results, multivariable logistic analysis
- Consecutive patients
- Preliminary results
- Multivariable logistic analysis
Main finding
As reported in the abstract
- Significantly different cognitive performance vs baseline in women treated with extended-release metformin (p: 0.007)
- Role of extended-release metformin confirmed by multivariable logistic analysis adjusting for potential confounders
- Women, extended-release metformin vs Women, untreated: p: 0.041
- Women, extended-release metformin vs Men, extended-release metformin: p: 0.016
- Women, extended-release metformin vs Women, regular metformin: p: 0.048
- Preliminary results
Observational data: associations, not effects.
Original publication
Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study. Cardiovasc Diabetol. Published 21 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →